Factors contributing to caregivers' stress and burden in Parkinson's disease

Santos‐García, Diego; Fuente‐Fernández, Raúl de la

doi:10.1111/ane.12305

Cited by 68 publications

(93 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Mobility impairment, as well as activities of daily living, have been reported as a burden for caregivers [21]. Increasing disabilities in PD construct a stigma that can lead to social isolation and emotional distress, which, in turn, causes burden to caregivers [22].…”

Section: Discussionmentioning

confidence: 99%

Quality of Life and Caregivers' Burden of Parkinson's Disease

et al. 2017

View full text Add to dashboard Cite

Aim: This study focused on the impact of the clinical features on the quality of life (QoL) of Parkinson's disease (PD) patients and of their caregivers. Methods: This study included PD patients along with their caregivers and was undertaken at the Malaysian Parkinson's Disease Association from June 2016 to November 2016. Clinical features of PD patients were assessed using the Movement Disorder Society revised Unified Parkinson Disease Rating Scale; the Hoehn and Yahr stage and the Schwab and England Activities of Daily Living Scale were used to assess the severity and the ability of PD patients respectively. QoL of PD patients was measured using the Parkinson's Disease Questionnaire-39 (PDQ-39). The revised version of the Zarit Burden Interview assessed caregiver burden. Results: At least one of the clinical features affected PD patients' QoL, and at least one of the QoL domains affected the caregivers' burden. Clinical features “saliva and drooling” and “dyskinesia” explained 29% of variance in QoL of PD patients. The QoL domains “stigma,” along with “emotional well-being” explained 48.6% of variance in caregivers' burden. Conclusions: The clinical features “saliva and drooling” and “dyskinesia” impacted the QoL of PD patients, and the QoL domains “stigma” and “emotional well-being” of PD patients impacted their caregivers' burden.

show abstract

Section: Discussionmentioning

confidence: 99%

Quality of Life and Caregivers' Burden of Parkinson's Disease

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Sixty‐eight PD patients from the cohort ( n = 150) (Santos‐García and de la Fuente‐Fernández , ) were receiving DA therapy at baseline: 30 pramipexole, 20 rotigotine, 17 ropinirole, and one pramipexole + rotigotine. Seven patients died and two cases (taking ropinirole) were lost to follow‐up.…”

Section: Resultsmentioning

confidence: 99%

“…We conducted a retrospective chart review of the follow‐up of a subgroup of nondemented PD patients receiving a DA ( n = 68; 60.3% males, 69.3 ± 9.2 years old) from a cohort ( n = 150) previously studied in detail (Santos‐García and de la Fuente‐Fernández , ). The patients from the cohort who were receiving a DA, such as pramipexole, ropinirole, and rotigotine at baseline (cross‐sectional study conducted in 2012) were included in this study.…”

Section: Methodsmentioning

confidence: 99%

Causes and factors related to dopamine agonist withdrawal in Parkinson′s disease

et al. 2016

View full text Add to dashboard Cite

BackgroundAlthough dopamine agonists (DAs) are useful in Parkinson′s disease (PD), they are not frequently used in elderly patients due to adverse effects. However, there is a lack of evidence because few elderly PD patients are enrolled in clinical trials.Aims of the studyThe aims of this study were to analyze the reasons of DA withdrawal (DAW) in a group of PD patients in clinical practice and to identify the related factors. Specifically, we studied the effect of age, comorbidity, and polypharmacy as potential risk factors for DAW.MethodsA retrospective chart review of the follow‐up (from May, 2012 to March, 2015) of a subgroup of PD patients receiving a DA (n = 68; 60.3% males, 69.3 ± 9.2 years old) from a cohort (n = 150) previously studied in detail in 2012 was used to identify predictive factors of DAW.ResultsThe DAW percentage was 18.2% (12/66; follow‐up of 690.2 ± 232.6 days). DAW causes were cognitive impairment (3), reduction therapy (3), hallucinations (2), dyskinesia (2), and excessive diurnal somnolence (2). Only a higher levodopa daily dose (HR 1.003; 95% CI 1.001–1.006; P = 0.044) was an independent predictor of DAW after adjustment for other explanatory variables.ConclusionsThe frequency of DAW was low. Advanced age alone is not a contraindication to the administration of DAs.

show abstract

“…Parkinson’s disease (PD) is a chronic and progressive neurodegenerative disorder characterised by physical and psychological symptoms that result in motor disability, neuropsychiatric symptoms and loss of autonomy [1, 2]. PD is the second most common neurodegenerative disorder after Alzheimer’s disease affecting approximately 1-2 % of the population over 60 years of age and 4 % of those aged 80 years worldwide [3].…”

Section: Introductionmentioning

confidence: 99%

“…These common manifestations that affect the quality of life (QoL) of carers of individuals with PD are frequently associated with the severity of symptoms of patients, progression disease and patient disability [14]. Several studies examining the role of caregiving in Spain and other Western European countries have found that patient disability and mood disturbances contribute to caregiver’s burden and stress as well as placing strain on the family unit as a whole [1, 16, 17]. In addition, the demands of caring may result in an increase in marital dissatisfaction since caregiving may result in a lack of leisure activities, social isolation and low levels of perceived social support [18].…”

Section: Introductionmentioning

confidence: 99%

Spanish version of the Parkinson’s Disease Questionnaire–Carer (PDQ-Carer)

Ferrer‐Cascales

Cabañero‐Martínez

Sánchez‐SanSegundo

et al. 2016

Health Qual Life Outcomes

View full text Add to dashboard Cite

BackgroundParkinson’s caregivers are frequently affected by a range of physical and psychological factors affecting to the quality of life (QoL) of patients and caregivers. However, while there are well-validated QoL instruments for patients, few specific measures has been developed for caregivers of patients with PD. This study examined the psychometric properties of the Spanish version of the Parkinson Disease Questionnaire–Carer (PDQ-Carer) for use in PD caregivers.MethodsThe PDQ-Carer and the Short Form-36 Health Survey (SF-36) were completed by sample of 73 caregivers of patients with PD in Spain (71.8 % females; 63.6 ± 12.3 years old).ResultsPsychometric analysis confirmed the reliability and validity of the Spanish version of the PDQ-Carer. The internal consistency was found to be satisfactory for the four PDQ-Carer domains: Personal and Social Activities, Depression and Anxiety, Self-care and Stress with Cronbach’s alpha values ranging 0.80 to 0.95. The PDQ-Carer was significantly correlated with the eight SF-36 domains (r = -0.31 to -0.59, p < 0.001) supporting the concurrent validity of the instrument.ConclusionsOverall, these results provide preliminary evidence of the utility of the Spanish version of the PDQ-Carer in non-professionals caregivers

show abstract

Factors contributing to caregivers' stress and burden in Parkinson's disease

Abstract: Disability (ADLS) and mood (BDI) of patients with PD are the main factors contributing to burden and stress in caregivers.

Cited by 68 publications

References 48 publications

Quality of Life and Caregivers' Burden of Parkinson's Disease

Quality of Life and Caregivers' Burden of Parkinson's Disease

Causes and factors related to dopamine agonist withdrawal in Parkinson′s disease

Spanish version of the Parkinson’s Disease Questionnaire–Carer (PDQ-Carer)

Contact Info

Product

Resources

About